Ioversol · IOVERSOL 636 mg/mL · Injection · Intra-Arterial; Intravenous · Liebel-Flarsheim Company LLC
NDC 00019-1332-00 · 20 SYRINGE, PLASTIC in 1 CARTON / 100 mL in 1 SYRINGE, PLASTIC · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. One of its named manufacturing plants, Liebel-Flarsheim Company LLC, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Liebel-Flarsheim Company LLC | IOVERSOL 678 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Liebel-Flarsheim Company LLC | IOVERSOL 741 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Liebel-Flarsheim Company LLC | IOVERSOL 636 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Optiray 300 — NDC 00019-1332-00," retrieved September 3, 2026, https://drugdashboards.com/drug/00019133200.
Free to cite with attribution — see how the data is put together.